Allogene Therapeutics Inc 2024年度报告

Message from Our President and CEO Dear Fellow Stockholders, As we reflect on 2024, I’m proud of the significant progress we made toward delivering onAllogene’s mission to transform the future of cancer and autoimmune care through theongoing development of our investigational allogeneic CAR T cell products. With a focusedstrategy, disciplined execution, and shared commitment across our team and Board, weachieved significant milestones across our clinical pipeline, strengthened our manufacturingcapabilities, and enhanced our corporate governance - each an important component of long-term value. During 2024, we significantly advanced our lead clinical development programs. We launchedthe pivotal Phase 2 ALPHA3 trial, positioning cema-cel as a component of first-lineconsolidation therapy for LBCL. This trial represents the opportunity to redefine the standard ofcare by reaching patients earlier, when disease burden is low and outcomes are potentiallymore favorable. We also received clearance of our investigational new drug (IND) applicationfrom the U.S. FDA for the RESOLUTION trial of ALLO-329 in autoimmune diseases, andearned RMAT designation for ALLO-316 in renal cell carcinoma. These advances reflect ourleadership in the allogeneic CAR T field and the dedication of our team, none of which wouldbe possible without your continued support. We recognize that innovation alone is not enough. Building a sustainable company alsomeans holding ourselves to high standards in governance, fiscal discipline, and stakeholderresponsiveness. In 2024, we executed an active stockholder engagement program, includingtargeted outreach following our annual meeting. We appreciated the thoughtful feedback and,in response, implemented several enhancements to our executive compensation practicesand disclosures. Our Board remains focused on aligning our governance structures with ourevolving operational profile. Looking ahead, we expect 2025 to be a defining year. With enrollment underway in theALPHA3 trial and set to begin in the RESOLUTION trial, we are entering a period with thepotential to transform how CAR T therapies are used in patient care, while laying thefoundation for registration paths in multiple programs. As we do so, we remain grounded in ourcommitment to scientific excellence, integrity, and the patients we ultimately serve. Thank you for your trust and support as we work to bring the next revolution in cell therapy topatients. Sincerely, IN MEMORIAM David Bonderman (1942–2024)Director, Allogene Therapeutics, Inc. (2018–2024) The Board of Directors and executive leadership of Allogene Therapeutics, Inc. respectfully acknowledge the passing ofDavid Bonderman, a founding member of our Board of Directors. Mr. Bonderman served with distinction from 2018 untilhis passing in 2024. Mr. Bonderman brought to Allogene a unique combination of strategic insight, business acumen, and a deep commitmentto innovation. His decades of experience as a global investor and leader in the private equity industry provided invaluableguidance during Allogene’s formative years and throughout its evolution as a clinical-stage biotechnology company. Mr. Bonderman was a strong advocate for the promise of allogeneic CAR T therapy, and his counsel played a significantrole in advancing our mission to revolutionize cancer treatment. His dedication to the Company, sound judgment, andsteady leadership made a lasting impact on Allogene and on all those who had the privilege of working with him. We are deeply grateful for Mr. Bonderman’s service and extend our heartfelt condolences to his family, friends, andcolleagues. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_________________________________ (Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedDecember 31, 2024OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934FOR THE TRANSITION PERIOD FROMTOCommission File Number001-38693_________________________________ Allogene Therapeutics, Inc. (Exact name of Registrant as specified in its Charter)_________________________________ Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) d